ENHERTU Approved in the U S for the Treatment of Patients With Previously Treated HER2 Positive Advanced Gastric Cancer financialbuzz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialbuzz.com Daily Mail and Mail on Sunday newspapers.
Daiichi Sankyo Company, Limited: ENHERTU Approved in the U.S. for the Treatment of Patients With Previously Treated HER2 Positive Advanced Gastric Cancer
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca s
ENHERTU (fam-trastuzumab deruxtecan-nxki) has been approved in the U.S. for the treatment of adult patients with locally advanced or metastatic HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210115005582/en/
ENHERTU (fam-trastuzumab deruxtecan-nxki) Vials on Conveyor Belt PP-US-EN-0383 2021 Daiichi Sankyo, Inc. AstraZeneca
In the U.S., gastric cancer is more frequently diagnosed in the advanced stage, with only approximately 5% of patients surviving five years.
First HER2 directed medicine approved for patients with gastric cancer in a decadeTOKYO & MUNICH & BASKING RIDGE, N.J. (BUSINESS WIRE) Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved in the U.S. for the treatment of adult pa.